FDANews
FDAnews Device Daily Bulletin

Myriad to Present Data on Tests Aimed at Gynecological Cancers

March 21, 2016

Findings from studies evaluating Myriad Genetics’ myRisk Hereditary Cancer test in patients with endometrial cancer who had previously undergone tumor testing demonstrate an ability to identify 60 percent more mutations, the company says.

The myRisk test uses sequencing technology to identify 25 genes related to melanoma, as well as breast, colon, endometrial, pancreatic, prostate and gastric cancers.

The second study demonstrated the ability of combined three biomarker myChoice HRD test in survival prediction in patients with ovarian cancer, according to the company. — Anisa Jibrell